FY22 results meeting to take place as a hybrid event on Thursday, 23 March 2023 at 3pm CET


Louvain-la-Neuve, Belgium, 20 February 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2022 on Thursday, 23 March 2023 at 7am CET.

Conference Call Information

Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a hybrid event to present the full year results, including a conference call and webcast, followed by a Q&A session.

The conference call, conducted in English, will be held on Thursday,23 March 2023 at 3pm CET / 2pm GMT / 10am EDT / 7amPDT as a Teams webinar and can be accessed online via this link.


If you would like to join by phone only, please dial (Phone conference ID 745 901 390#):

Belgium:                     +32 2 890 97 20

UK:                             +44 20 3321 5200

NL:                              +31 20 708 6901

LU:                              +352 27 87 00 02

US:                             +1 347-991-7591

FR:                              +33 1 70 99 53 51


The presentation will be available on IBA’s investor relations website and on:

https://www.iba-worldwide.com/content/iba-full-year-2022-results-press-release-publication-date-conference-call-details shortly before the call.


To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.




 About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com